Enhanced virus safety of a solvent/detergent-treated antihemophilic factor IX concentrate by dry-heat treatment

Biotechnology and Bioprocess Engineering

Volumn 11, Issue 1, 2006, Pages 19-25

  Shin, Jeong Sup ^a,b   Choi, Yong Woon ^a   Sung, Hark Mo ^a   Ryu, Yeon Woo ^b   Kim, In Seop ^c  

^a Green Cross Company   (South Korea)

^b Ajou University   (South Korea)

^c Hannam University   (South Korea)

Author keywords

Antihemophilic factor IX; Dry heat treatment; Hepatitis A virus; Virus inactivation

Indexed keywords

BLOOD CLOTTING FACTOR 9; DETERGENT; SOLVENT;

ARTICLE; BOVINE HERPES VIRUS; ENCEPHALOMYOCARDITIS VIRUS; FREEZE DRYING; HEPATITIS A VIRUS; HYPERTHERMIC THERAPY; INTERMETHOD COMPARISON; NONHUMAN; PORCINE PARVOVIRUS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STABILITY; SAFETY; SENSITIVITY ANALYSIS; VIRUS INACTIVATION;

BOVINAE; ENCEPHALOMYOCARDITIS VIRUS; HEPATITIS A VIRUS; HERPESVIRIDAE; MURINAE; PORCINE PARVOVIRUS;

EID: 33644769488     PISSN: 12268372     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02931863     Document Type: Article

References (30)

1. O'Connell, N. M. (2003) Factor XI deficiency-from molecular genetics to clinical management. Blood Coagul. Fibrinolysis 14 Suppl 1: S59-S64.
2. Berkman, S. A. (1988) Infectious complications of blood transfusion. Blood Rev. 2: 206-210.
3. Mosley, J. W. and J. Rakela (1999) Foundling viruses and transfusion medicine. Transfusion 39: 1041-1044.
4. Klein, H. G. (2005) Pathogen inactivation technology: cleansing the blood supply. J. Intern. Med. 257: 224-237.
5. Tabor, E. (1999) The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 39: 1160-1168.
6. Robertson, B. H. and D. D. Erdman (2000) Non-enveloped viruses transmitted by blood and blood products. Dev. Biol. Standard. 102: 29-35.
7. Morgenthaler, J. J. (2000) New development in plasma fractionation and virus inactivation. Vox Sang. 78 Suppl 2: 217-221.
8. Laub, R. and P. Strengers (2002) Parvovirus and blood products. Pathol. Biol. (Paris) 50: 339-348.
9. Burnouf, T. and M. Radosevich (2000) Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev. 14: 94-110.
10. Robinson, S. M., H. Schwinn, and A. Smith (1992) Clotting factors and hepatitis A. Lancet 340: 1465.
11. Chudy, M., I. Budek, B. Keller-Stanislawski, K. A. McCaustland, S. Neidhold, B. H. Robertson, C. M. Nubling, R. Seitz, and J. Lower (1999) A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J. Med. Virol. 57: 91-99.
12. Lawlor, E., S. Graham, E. Davidson, P. L. Yap, C. Cunningham, H. Daly, and I. J. Temperley (1996) Hepatitis A transmission by factor IX concentrates. Vox. Sang. 71: 126-128.
13. Andrewes, C. (1989) Andrewes' Viruses of Vertebrates. pp. 120-145. Balliere Tindal, London, UK.
14. Kim, I. S., Y. W. Choi, S. R. Lee, and H. M. Sung (2004) Cold ethanol fractionation and heat inactivation of hepatitis A virus during manufacture of albumin from human plasma. Biotechnol. Bioprocess Eng. 9: 57-60.
15. Roberts, P. L. and H. Hart (2000) Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates. Biologicals 28: 185-188.
16. Arrighi, S., R. Rossi, M. G. Borri, V. Lesnikov, M. Lesnikova, E. Franco, M. Divizia, M. E. de Santis, and E. Bucci (1995) "In vitro" and in animal model studies on a double virus-inactivation factor VIII concentrate. Thromb. Haemost. 74: 868-873.
17. Powell J. S., M. Bush, J. Harrison, C. Abildgaard, E. Vosburgh, A. R. Thompson, and D. Hurst (2000) Safety and efficacy of solvent/ detergent-treated antihaemophilic factor with an added 80°C terminal dry heat treatment in patients with haemophilia A. Haemophilia 6: 140-149.
18. International Conference on Harmonisation (1998) Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability. Fed. Regist. 63: 51074-51084.
19. Kim, I. S., Y. W. Choi, S. R. Lee, Y. Kang, K. M. Lee, D. H. Park, H. S. Woo, and S. Lee (2002) Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine. Biotechnol. Bioprocess Eng. 7: 340-346.
20. Kim, I. S., Y. W. Choi, and S. R. Lee (2004) Optimization and validation of a virus filtration process for efficient removal of viruses from urokinase solution prepared from human urine. J. Microbiol. Biotechnol. 14: 140-147.
21. Kärber, J. (1931) Beitrag zur kollectiven Behandlung pharmakologische Reihenversuche. Arch. Exp. Pathol. Pharmakol. 162: 480-483.
22. Gummadi, S. N. (2003) What is the role of thermodynamics on protein stability? Biotechnol. Bioprocess Eng. 8: 9-18.
23. Kim, I. S., H. G. Eo, C. W. Park, C. E. Chang, and S. Lee (2001) Removal and inactivation of human immunodeficiency virus (HIV-1) by cold ethanol fractionation and pasteurization during the manufacture of albumin and immunoglobulins from human plasma. Biotechnol. Bioprocess Eng. 6: 25-30.
24. Carpenter, J. F., M. J. Pikal, B. S. Chang, and T. W. Randolph (1997) Rational design of stable lyophilized protein formulations: some practical advice. Pharm. Res. 14: 969-975.
25. Murgatroyd, K. (1997) The freeze drying process. pp. 1-58. In: P. Cameron (eds.). Good Pharmaceutical Freeze-Drying Practice. Interpharm Press, Buffalo Grove, IL, USA.
26. Dichtelmuller, H., D. Rudnick, B. Breuer, R. Kotitschke, M. Kloft, A. Darling, E. Watson, B. Flehmig, S. Lawson, and G. Frosner (1996) Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100°C. Biologicals 24: 125-130.
27. Kim, I. S., Y. W. Choi, S. R. Lee, H. S. Woo, and S. Lee (2001) Removal and inactivation of viruses during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. Biotechnol. 11: 497-503.
28. Kim, I. S. (2003) Comparative inactivation of Hepatitis A virus and Murine Encephalomyocarditis virus to various inactivation processes. Kor. J. Microbiol. 39: 242-247.
29. Kim, I. S., Y. W. Choi, S. R. Lee, M. S. Lee, K. H. Huh, and S. Lee (2001) Removal and inactivation of hepatitis A virus during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. 39: 67-73.
30. Boschetti, N., I. Niederhauser, C. Kempf, A. Stuhler, J. Lower, and J. Blumel (2004) Different susceptibility of B19 virus and mice minute virus to low pH treatment. Transfusion 44: 1079-1086.